Categorization of Tests
Guidance for Clinical Laboratory Improvement Amendments (CLIA) test complexity categorization provisions.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: December 31, 2019
Since November 13, 2003, the Food and Drug Administration (FDA) has had the authority to implement the Clinical Laboratory Improvement Amendments (CLIA) test complexity categorization provisions, which includes, but is not limited to the following:
- Interpreting the CLIA provisions related to complexity categorization;
- Holding public workshops and meetings on CLIA complexity categorization; and,
- Developing and issuing implementing rules and guidance for CLIA complexity categorization.
The FDA CLIA database contains the commercially-marketed in vitro test systems categorized by FDA since January 31, 2000, as well as tests categorized by Centers for Disease Control and Prevention prior to that date.
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.